Resmed
ResMed Inc., a leading player in the sleep and respiratory care industry, is headquartered in the United States, with significant operations across Europe, Asia, and Australia. Founded in 1989, ResMed has consistently innovated in the development of cloud-connected devices and software solutions that enhance patient care and improve quality of life for those with sleep apnoea and chronic obstructive pulmonary disease (COPD). The company’s core offerings include advanced continuous positive airway pressure (CPAP) devices, portable oxygen concentrators, and digital health solutions, all designed to provide seamless integration and user-friendly experiences. ResMed's commitment to research and development has positioned it as a market leader, recognised for its pioneering technologies and significant contributions to the field of sleep medicine. With a strong focus on improving patient outcomes, ResMed continues to set benchmarks in the healthcare industry.
DitchCarbon Score
How does Resmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Resmed's score of 35 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Resmed's reported carbon emissions
In 2023, ResMed reported total carbon emissions of approximately 28,391,000 kg CO2e, with Scope 1 emissions at about 4,453,000 kg CO2e and Scope 2 emissions at around 23,939,000 kg CO2e. This represents a decrease from 2022, where total emissions were approximately 28,658,000 kg CO2e. Over the years, ResMed has shown fluctuations in its emissions, with a notable peak in 2021 at approximately 23,028,000 kg CO2e. The company has disclosed emissions data for Scope 1 and Scope 2, but there is no specific information available regarding Scope 3 emissions or any formal reduction targets set under the Science Based Targets initiative (SBTi). ResMed's commitment to addressing climate change is evident through its ongoing efforts to monitor and report emissions, although specific reduction initiatives or targets have not been outlined. The company continues to focus on improving its emissions intensity, which was approximately 6.7e-06 tonnes CO2e per million USD revenue in 2023. Overall, while ResMed has made strides in emissions reporting, further clarity on reduction commitments would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Resmed is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
